Corrigendum to“Challenges and opportunities of cfDNA analysisimplementation in clinical practice: Perspective of the International Societyof Liquid Biopsy (ISLB)”[Crit. Rev. Oncol. Hematol. 151 (July) (2020)102978]

Precision medicine was born with the development of new diagnostic techniques and targeted drugs, yielding better outcomes in cancer care. With the evolution and increasing sensitivity for detecting oncogenic drivers, liquid biopsies (LBs), specifically cell-free DNA (cfDNA) analysis, have been prop...

Full description

Autores:

Rolfo, Christian
Cardona-Mendoza, Andrés Felipe
Cristofanilli, Massimo
Paz-Ares, Luis
Díaz-Mochõn, Juan José
Durán, Ignacio
Raez, Luis Estuardo
Russo, Alessandro
LORENTE, JOSE A.
Malapelle, Umberto
Gil-Bazo, Ignacio
Jantus Lewintre, Eloisa
Pauwels, Patrick
Mok, Tony
Serrano, María José

Tipo de recurso:

Article of journal

Fecha de publicación:

2020

Institución:

Universidad El Bosque

Repositorio:

Repositorio U. El Bosque

Idioma:

eng

OAI Identifier:

oai:repositorio.unbosque.edu.co:20.500.12495/3907

Acceso en línea:

http://hdl.handle.net/20.500.12495/3907
https://doi.org/10.1016/j.critrevonc.2020.103058
https://repositorio.unbosque.edu.co

Palabra clave:

Liquid biopsy
Cell-free DNA
Perspective
ISLB
NGS
Precision oncology

Rights

openAccess

License

Acceso abierto